{"schema_version":"secwatch.filing_event.v1","accession":"0001376339-26-000012","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.944292+00:00","generated_at":"2026-05-16T00:11:06.250559+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MiMedx posts record Q4 sales $118M (+27% YoY); 2026 guidance $340-360M; $100M buyback","bullets":["Q4 net sales $118M, +27% YoY; full-year $419M, +20% YoY.","Q4 GAAP net income $15M ($0.10 EPS); Adjusted EBITDA $29M (25% margin).","2026 net sales guidance $340-360M, down from 2025 actual; Adj EBITDA margin mid-to-high teens.","Board authorizes $100M share repurchase program over two years.","Cash & equivalents $166M; net cash $148M; SG&A up 18% to $266M on higher commissions."],"urls":{"canonical":"https://secwatch.observer/filing/0001376339-26-000012","json":"https://secwatch.observer/filing/0001376339-26-000012.json","markdown":"https://secwatch.observer/filing/0001376339-26-000012.md","text":"https://secwatch.observer/filing/0001376339-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000137633926000012/0001376339-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000137633926000012/mdxg-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:11:06.250559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}